BFEC
CRSP icon

Benjamin F. Edwards & Company’s CRISPR Therapeutics CRSP Stock Holding History

Benjamin F. Edwards & Company’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$1.84M Buy
34,081
+33,418
+5,040% +$1.93M 0.03% 388
2024
Q1 		$45K Buy
663
+563
+563% +$40.3K ﹤0.01% 1328
2023
Q4 		$6K Hold
100
– – ﹤0.01% 1796
2023
Q3 		$5K Hold
100
– – ﹤0.01% 1546
2023
Q2 		$6K Hold
100
– – ﹤0.01% 1495
2023
Q1 		$5K Hold
100
– – ﹤0.01% 1529
2022
Q4 		$4K Hold
100
– – ﹤0.01% 1613
2022
Q3 		$7K Hold
100
– – ﹤0.01% 1458
2022
Q2 		$6K Hold
100
– – ﹤0.01% 1486
2022
Q1 		$6K Hold
100
– – ﹤0.01% 1470
2021
Q4 		$8K Hold
100
– – ﹤0.01% 1425
2021
Q3 		$11K Hold
100
– – ﹤0.01% 1349
2021
Q2 		$16K Sell
100
-100
-50% -$12.2K ﹤0.01% 1268
2021
Q1 		$24K Buy
+200
New +$30.2K ﹤0.01% 1158
2019
Q4 		– Sell
-400
Closed -$16K – 1873
2019
Q3 		$16K Sell
400
-827
-67% -$39.5K ﹤0.01% 1254
2019
Q2 		$58K Hold
1,227
– – ﹤0.01% 862
2019
Q1 		$44K Sell
1,227
-400
-25% -$13.8K ﹤0.01% 897
2018
Q4 		$46K Buy
1,627
+800
+97% +$27.8K ﹤0.01% 846
2018
Q3 		$37K Buy
827
+350
+73% +$18.3K ﹤0.01% 941
2018
Q2 		$28K Buy
477
+377
+377% +$21.5K ﹤0.01% 998
2018
Q1 		$5K Hold
100
– – ﹤0.01% 1399
2017
Q4 		$2K Buy
+100
New +$1.9K ﹤0.01% 1478

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Benjamin F. Edwards & Company's CRSP Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its CRISPR Therapeutics (CRSP) stake by 5,040% in Q2 2024, buying an estimated $1.93M and bringing the position to 34,081 shares worth $1.84M. The position accounts for 0.03% of the portfolio, ranked #388.

Benjamin F. Edwards & Company first reported a position in CRSP in Q4 2017 and has held it in 22 quarters since. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Benjamin F. Edwards & Company held 34,081 shares of CRISPR Therapeutics worth $1.84M as of Q2 2024.
  • Benjamin F. Edwards & Company bought 33,418 CRISPR Therapeutics shares in Q2 2024, an estimated $1.93M.
  • CRISPR Therapeutics made up 0.03% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #388 holding.
  • Benjamin F. Edwards & Company first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 22 quarters since.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.